相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors
Kyung Hae Jung et al.
CLINICAL CANCER RESEARCH (2019)
EAGLE: A phase 3, randomized, open-label study of durvalumab (D) with or without tremelimumab (T) in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Lisa F. Licitra et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy
Dan P. Zandberg et al.
EUROPEAN JOURNAL OF CANCER (2019)
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Macrophages in the microenvironment of head and neck cancer: potential targets for cancer therapy
Diane Evrard et al.
ORAL ONCOLOGY (2019)
Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1-Low/Negative Recurrent or Metastatic HNSCC The Phase 2 CONDOR Randomized Clinical Trial
Lillian L. Siu et al.
JAMA ONCOLOGY (2019)
Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012
Ranee Mehra et al.
BRITISH JOURNAL OF CANCER (2018)
Immuno-oncology in head and neck squamous cell cancers: News from clinical trials, emerging predictive factors and unmet needs
Stefano Cavalieri et al.
CANCER TREATMENT REVIEWS (2018)
Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression
Robert L. Ferris et al.
ORAL ONCOLOGY (2018)
Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors
Aaron M. Goodman et al.
JAMA ONCOLOGY (2018)
Safety and clinical activity of atezolizumab in head and neck cancer: results from a phase I trial
A. D. Colevas et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Biomarkers predictive of response to pembrolizumab in head and neck cancer (HNSCC)
Tanguy Y. Seiwert et al.
CANCER RESEARCH (2018)
Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037)
Tara C. Mitchell et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy.
Corey Christian Foster et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Safety and preliminary efficacy of talimogene laherparepvec (T-VEC) in combination (combo) with pembrobrolizumab (Pembro) in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): A multicenter, phase 1b study (MASTERKEY-232).
Kevin J. Harrington et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Health-related quality of life (HRQoL) of pembrolizumab (pembro) vs standard of care (SOC) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in KEYNOTE-040.
Ezra E. W. Cohen et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Immune Checkpoint Inhibition in Head and Neck Cancer
Martin David Forster et al.
FRONTIERS IN ONCOLOGY (2018)
1117TiPIMvoke010: Randomized phase III study of atezolizumab (atezo) as adjuvant monotherapy after definitive therapy of squamous cell carcinoma of the head and neck (SCCHN)
R Haddad et al.
ANNALS OF ONCOLOGY (2018)
1044OA phase Ib/II study (SCORES) of durvalumab (D) plus danvatirsen (DAN; AZD9150) or AZD5069 (CX2i) in advanced solid malignancies and recurrent/metastatic head and neck squamous cell carcinoma (RM-HNSCC): Updated results
E E W Cohen et al.
ANNALS OF ONCOLOGY (2018)
LBA8_PRKEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC)
B Burtness et al.
ANNALS OF ONCOLOGY (2018)
LAG-3 inhibits the activation of CD4+ T cells that recognize stable pMHCII through its conformation-dependent recognition of pMHCII
Takumi Maruhashi et al.
NATURE IMMUNOLOGY (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Beyond the Percentages of PD-L1-Positive Tumor Cells: Induced Versus Constitutive PD-L1 Expression in Primary and Metastatic Head and Neck Squamous Cell Carcinoma
Theresa Scognamiglio et al.
HEAD & NECK PATHOLOGY (2018)
Frameshift events predict anti-PD-1/L1 response in head and neck cancer
Glenn J. Hanna et al.
JCI INSIGHT (2018)
Activation of immune responses in patients with relapsed-metastatic head and neck cancer (CONFRONT phase I-II trial): Multimodality immunotherapy with avelumab, short-course radiotherapy, and cyclophosphamide
Marco C. Merlano et al.
CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY (2018)
Gene-expression profiling to predict responsiveness to immunotherapy
N. B. Jamieson et al.
CANCER GENE THERAPY (2017)
Biological mechanisms of immune escape and implications for immunotherapy in head and neck squamous cell carcinoma
Jennifer D. Moy et al.
EUROPEAN JOURNAL OF CANCER (2017)
IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
Mark Ayers et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial
Christopher R. Heery et al.
LANCET ONCOLOGY (2017)
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial
Kevin J. Harrington et al.
LANCET ONCOLOGY (2017)
Tumor Mutational Burden and Response Rate to PD-1 Inhibition
Mark Yarchoan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
FDA Approval Summary: Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma with Disease Progression on or After Platinum-Containing Chemotherapy
Erin Larkins et al.
ONCOLOGIST (2017)
The prognostic role of tumor infiltrating T-lymphocytes in squamous cell carcinoma of the head and neck: A systematic review and meta-analysis
Emma J. de Ruiter et al.
ONCOIMMUNOLOGY (2017)
Safety of pembrolizumab with chemoradiation (CRT) in locally advanced squamous cell carcinoma of the head and neck (LA-SCCHN).
Steven Francis Powell et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Epacadostat plus pembrolizumab in patients with SCCHN: Preliminary phase VII results from ECHO-202/KEYNOTE-037.
Omid Hamid et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Heterogeneous Tumor-Immune Microenvironments among Differentially Growing Metastases in an Ovarian Cancer Patient
Alejandro Jimenez-Sanchez et al.
CELL (2017)
Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy
Nabil F. Saba et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Nivolumab (Nivo) vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use.
Robert L. Ferris et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Fibroblasts and macrophages: Key players in the head and neck cancer microenvironment
Kusumawadee Utispan et al.
JOURNAL OF ORAL BIOSCIENCES (2017)
Investigational drugs for head and neck cancer
Paolo Bossi et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2016)
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma
Adil I. Daud et al.
JOURNAL OF CLINICAL INVESTIGATION (2016)
Tumor- associated macrophages correlate with the clinicopathological features and poor outcomes via inducing epithelial to mesenchymal transition in oral squamous cell carcinoma
Yong Hu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2016)
Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial
Tanguy Y. Seiwert et al.
LANCET ONCOLOGY (2016)
Molecular and Biochemical Aspects of the PD-1 Checkpoint Pathway
Vassiliki A. Boussiotis
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Amidst the excitement: A cautionary tale of immunotherapy, pseudoprogression and head and neck squamous cell carcinoma
Shrujal S. Baxi et al.
ORAL ONCOLOGY (2016)
IL-8 promotes HNSCC progression on CXCR1/2-meidated NOD1/RIP2 signaling pathway
Leong-Perng Chan et al.
ONCOTARGET (2016)
Association between PD-L1 and HPV Status and the Prognostic Value of PD-L1 in Oropharyngeal Squamous Cell Carcinoma
Hae Su Kim et al.
CANCER RESEARCH AND TREATMENT (2016)
The head and neck cancer immune landscape and its immunotherapeutic implications
Rajarsi Mandal et al.
JCI INSIGHT (2016)
Differences in T-cell infiltrates and survival between HPV+ and HPV- oropharyngeal squamous cell carcinoma
Sanne Evelien Matlung et al.
FUTURE SCIENCE OA (2016)
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma
Robert H. I. Andtbacka et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy
Sandip Pravin Patel et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Viral Infection of Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-cell Responses
Norman Woller et al.
MOLECULAR THERAPY (2015)
Rationale for combined blockade of PD-1 and CTLA-4 in advanced head and neck squamous cell cancer - Review of current data
Mark S. Swanson et al.
ORAL ONCOLOGY (2015)
Head and neck cancer subtypes with biological and clinical relevance: Meta-analysis of gene-expression data
Loris De Cecco et al.
ONCOTARGET (2015)
The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis
Q. Yao et al.
INTERNATIONAL JOURNAL OF IMMUNOGENETICS (2015)
Genetic regulation and potentially therapeutic application of cancer-associated fibroblasts in oral cancer
Jingyi Wang et al.
JOURNAL OF ORAL PATHOLOGY & MEDICINE (2014)
Tumor Microenvironment in Head and Neck Squamous Cell Carcinoma
Joseph M. Curry et al.
SEMINARS IN ONCOLOGY (2014)
Tumoral indoleamine 2,3-dioxygenase expression predicts poor outcome in laryngeal squamous cell carcinoma
Jin Ye et al.
VIRCHOWS ARCHIV (2013)
The Tumor Microenvironment Contribution to Development, Growth, Invasion and Metastasis of Head and Neck Squamous Cell Carcinomas
Sittichai Koontongkaew
JOURNAL OF CANCER (2013)
Targeting STAT3 inhibits growth and enhances radiosensitivity in head and neck squamous cell carcinoma
Makoto Adachi et al.
ORAL ONCOLOGY (2012)
Human Papillomavirus and Survival of Patients with Oropharyngeal Cancer
K. Kian Ang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients
Jean-Pierre Pignon et al.
RADIOTHERAPY AND ONCOLOGY (2009)
Tumor Infection by Oncolytic Reovirus Primes Adaptive Antitumor Immunity
Robin J. Prestwich et al.
CLINICAL CANCER RESEARCH (2008)
Platinum-based chemotherapy plus cetuximab in head and neck cancer
Jan B. Vermorken et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Phase II study of combination cetuximab and weekly paclitaxel in patients with metastatic/recurrent squamous cell carcinoma of head and neck (SCCHN): Spanish Head and Neck Cancer Group (TTCC)
R. Hitt et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy
Jan B. Vermorken et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms
RV Parry et al.
MOLECULAR AND CELLULAR BIOLOGY (2005)
A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy
X León et al.
CLINICAL ONCOLOGY (2005)
分享论文
